Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Investigator & Subject Blinded, Sponsor Unblinded, Placebo-Controlled, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia

NCT06005428 is registered in ClinicalTrials.gov with Cardurion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06005428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06005428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Investigator & Subject Blinded, Sponsor Unblinded, Placebo-Controlled, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
November 7, 2023
Completion date
May 31, 2025
Enrollment
7 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cpvt1, heart defects, congenital, heart diseases, ventricular tachycardia